Neomidantan is used: with Parkinson’s syndrome to eliminate rigidity, tremor, hypokinesia, akinesia; with extrapyramidal side effects of neuroleptics and other drugs (early dyskinesia, akathisia, parkinsonism).
Neomidantan composition and form of release
Active ingredient: amantadine sulfate (100 mg).
Produced in capsule form.
It is an antiparkinsonian drug. Increases the concentration of dopamine within the cell by increasing the release of dopamine and blocking its reuptake in presynaptic neurons. Inhibits NMDA receptor-mediated release of acetylcholine, exhibiting anticholinergic effects.
Neomidantan is used:
- with Parkinson’s syndrome to eliminate rigidity, tremor, hypokinesia, akinesia;
- with extrapyramidal side effects of neuroleptics and other drugs (early dyskinesia, akathisia, parkinsonism).
- with intolerance to the components of the drug;
- with epilepsy, other seizures;
- with severe kidney failure;
- with peptic ulcer;
- with decompensated heart failure (NYHA stage IV);
- with cardiomyopathy, myocarditis;
- with AV blockade II, III degree;
- with bradycardia (heart rate less than 55 beats / minute);
- with an extended Q – T interval (Q – Tc more than 420 ms) or noticeable U-waves, congenital Q – T syndrome;
- with severe ventricular arrhythmia, incl. chaotic polymorphic ventricular tachycardia;
- with simultaneous treatment with drugs that cause prolongation of the Q – T interval;
- with hypokalemia, hypomagnesemia.
Application during pregnancy and lactation
Method of administration and dosage
Neomidantan is administered orally after meals no later than 16:00.
The standard dose is 100 mg per day for the first 4-7 days with a further increase in the dose by 100 mg once a week until a clinical effect is achieved.
Intoxication symptoms: acute toxic psychosis (confusion, visual hallucinations, coma, myoclonus), agitation, ataxia, tremor, blurred vision, dysarthria, lethargy, neuromuscular disorders, motor restlessness, hyperreflexia, convulsions, torsional spasms, extrapyramidal pupils, confusion, dysphagia, disorientation, visual hallucinations, delirium, myoclonus, vomiting, hyperventilation, dry mouth, pulmonary edema, respiratory distress syndrome, respiratory failure, arterial hypertension, cardiac arrhythmia, an attack of angina pectoris, tachycardia, arrest kidney dysfunction, urinary retention.
Treatment: induction of vomiting, gastric lavage, use of sorbents. Provides support for vital functions, adequate hydration, sedation.
- Neurological disorders: movement disorders, dizziness, orthostatic disorders, blurred vision, epileptic seizures, myoclonus, peripheral neuropathy, anxiety, cephalalgia, drowsiness / insomnia, fever, weakness, ataxia, decreased concentration, slurred speech, irritability, paresthesia, depression, depression, consciousness, tremor, disorientation, dyskinesia, suicidal thoughts / intentions, stupor, neuroleptic malignant syndrome, hypomania / mania, delirium, nightmares, hallucinations. sleep disorders, mental agitation, paranoid exogenous psychosis.
- Hematological disorders: leukopenia.
- Ophthalmic disorders: temporary loss of vision, edema of the corneal epithelium, oculocutaneous crises, decreased visual acuity, mydriasis.
- Cardiovascular disorders: “marbled skin”, cardiac arrhythmia, orthostatic hypotension, peripheral edema, tachycardia, heart failure.
- Digestive disorders: nausea, dry mouth, vomiting, anorexia, constipation, increased activity of liver enzymes, diarrhea.
- Dermatological disorders: eczematous dermatitis, skin rashes, increased sweating, itching, photosensitivity, allergy manifestations.
- Musculoskeletal disorders: rhabdomyolysis, myalgia, myasthenia gravis.
- Genitourinary disorders: urinary incontinence, urinary retention, changes in libido.
Storage conditions and periods
Store Neomidantan in its original packaging at temperatures up to +25 degrees. Good for 5 years after production.